RenovoRx, Inc. (RNXT) vs Xilio Therapeutics, Inc. (XLO)
A side-by-side comparison of RenovoRx, Inc. and Xilio Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
RNXT
RenovoRx, Inc.
$1.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
XLO
Xilio Therapeutics, Inc.
$9.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — RNXT vs XLO
growth of $100 · dividends reinvested · last 5yRNXT -75.0% (-24.2%/yr)XLO -95.9% (-47.3%/yr)RNXT compounded faster over this window
Log scale — wide-divergence pair
RNXT XLO
RNXT vs XLO: by the numbers
- •RNXT is the larger company ($63M vs $59M market cap).
- •Both run net losses; XLO's is the smaller (-34.06% vs -621.71% net margin).
Metrics side by side
Valuation
| Metric | RNXT | XLO |
|---|---|---|
| P/S ratio | 31.69 | 0.92 |
| P/B ratio | 6.97 | 0.82 |
Profitability
| Metric | RNXT | XLO |
|---|---|---|
| Gross margin | 70.88% | 99.46% |
| Operating margin | -1113.98% | -95.92% |
| Net margin | -621.71% | -34.06% |
| ROE | -136.82% | -30.21% |
| ROIC | -139.74% | -26.13% |
Growth (annualized)
| Metric | RNXT | XLO |
|---|---|---|
| Total return CAGR (5Y) | -23.80% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.